Sanofi must face trimmed US antitrust case over injectable insulin
MLex Summary: Sanofi-Aventis must face some of Mylan’s US antitrust claims over an injectable form of diabetes drug insulin glargine, according to a federal judge. District Judge Mark R. Hornak denied...To view the full article, register now.
Already a subscriber? Click here to view full article